Dogwood Therapeutics, Inc. (DWTX) Stock Score, Valuation & Financial Research

Dogwood Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for DWTX

Dogwood Therapeutics, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.35. These figures are a research snapshot, not a buy or sell recommendation.

What Dogwood Therapeutics, Inc. does

Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Dogwood Therapeutics is a development-stage biopharmaceutical company that does not currently generate revenue from product sales. Its business model relies on raising capital through equity or debt financing to fund the research, clinical development, and regulatory approval processes for its pipeline of pain and neuropathic disorder therapeutics.

Products and services

  • The company is developing two primary clinical-stage candidates: Halneuron, a highly purified tetrodotoxin (TTX) sodium channel modulator for pain, and SP16, an immunomodulator.

Brands and product families

  • Halneuron — A potent sodium channel modulator being developed as an analgesic. Source
  • SP16 — An immunomodulator candidate in the company's research pipeline. Source

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on unnamed third-party contract manufacturing organizations for the production of its clinical trial materials and drug candidates. Source

Business strengths to evaluate

  • Development-stage pipeline including first-in-class candidates Halneuron and SP16 Source

Business risks and research considerations

  • History of operating losses and dependence on future financing to sustain operations Source
  • Uncertainty of clinical trial success and regulatory approval processes Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

DWTX financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.35
Market capitalization:
45.4M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -36.04M
Free cash flow:
USD -15.62M
Cash:
USD 9.61M
Total debt:
USD 127.21K
EPS:
USD -8.95

What stands out

  • Free cash flow is USD -15.62M, negative for the stored period.
  • The balance sheet shows USD 9.61M of cash versus USD 127.21K of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 9.48M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for DWTX

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can DWTX fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is DWTX likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for DWTX to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of DWTX's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research DWTX

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.